查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1974331

抗體-寡核苷酸複合物市場：按寡核苷酸類型、結合方法、標靶化策略、應用和最終用戶分類－全球預測，2026-2030年

Antibody-oligonucleotide Conjugates Market by Oligonucleotide Type, Conjugation Methodology, Targeting Strategy, Application, End-User - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年抗體寡核苷酸複合物市場價值為 31.5 億美元，預計到 2025 年將成長至 34.2 億美元，複合年成長率為 8.89%，到 2030 年將達到 52.6 億美元。

主要市場統計數據
基準年 2024 31.5億美元
預計年份：2025年 34.2億美元
預測年份：2030年 52.6億美元
複合年成長率 (%) 8.89%

探索抗體-寡核苷酸複合物在精準醫療和診斷創新發展中的基礎和重要性。

抗體-寡核苷酸偶聯物代表了生物治療創新領域的前沿，它結合了單株抗體的靶向特異性和核酸技術的精細調控能力。作為一種用途廣泛的偶聯物，它們能夠將基因有效載荷精準地遞送至特定細胞群，從而為標靶治療和先進診斷開闢了新的前景。透過利用客製化的化學技術將寡核苷酸連接到抗體骨架上，研究人員正在克服傳統的遞送難題，提高組織穿透性並最大限度地減少脫靶效應。

從實驗室到臨床的整合方案：識別將重塑抗體寡核苷酸複合物開發的變革性技術轉變。

結合化學和分子設計的創新徹底改變了抗體-寡核苷酸複合物的片段。位點特異性結合技術的最新進展消除了複合物的異質性，從而實現了可重複的藥物動力學和可預測的體內分佈。同時，具有可調節穩定性的新型連接子結構能夠精確控制釋放動力學，從而提高治療指數並降低免疫抗原性。

2025年美國關稅的累積影響評估：對供應鏈研究投資與跨境合作研究的影響

2025年，美國實施的新關稅增加了抗體-寡核苷酸複合物生產供​​應鏈的複雜性。關鍵試劑（例如修飾寡核苷酸和特殊抗體）關稅的提高導致投入成本上升。因此，研發預算被重新分配以應對這些額外成本，從而導致採購和供應商選擇的策略性轉變。

揭示寡核苷酸類型、結合方法、標靶策略、應用領域和最終用戶等方面的關鍵細分見解。

清楚了解市場如何按關鍵參數細分，有助於獲得可操作的洞察。基於寡核苷酸類型的檢驗揭示了明顯的趨勢。反義寡核苷酸持續展現出強大的標靶基因敲低能力，而siRNA-抗體複合物則利用RNA干擾通道達到瞬時基因靜默。適體-抗體複合物因其雙重辨識能力而脫穎而出，而胜肽核酸在治療環境中則具有無與倫比的穩定性。

影響抗體寡核苷酸複合物的採用和成長模式的關鍵區域趨勢分析：北美和南美、歐洲、中東、非洲和亞太地區。

區域趨勢對抗體-寡核苷酸偶聯物的開發和應用有著深遠的影響。在美洲，成熟的生物製藥中心和強大的創業融資系統持續加速早期研發和轉化夥伴關係。此外，該地區的監管機構也積極與新型治療方法框架合作，促進了高效的臨床評估管道。

主要企業在抗體寡核苷酸複合物領域獲得競爭優勢的策略和創新亮點：全球參與企業概覽

抗體-寡核苷酸偶聯物領域的主要企業正透過專有平台技術和策略合作實現差異化競爭。創新生物技術公司正與學術機構建立合作關係，以儘早獲得新型連接子化學和寡核苷酸修飾技術。同時，成熟的製藥公司正利用其生產經驗加速規模化生產，並將偶聯物平台整合到更廣泛的生物製藥產品線中。

為指導產業領導者在抗體寡核苷酸偶聯療法領域進行創新最佳化和夥伴關係，提供切實可行的策略建議。

產業領導者應優先建構能夠適應多種結合方法的靈活製造生態系統。投資模組化生產線可根據計劃具體需求，在酵素法、化學法和親和性和法之間無縫切換。此外，與原料供應商建立早期合作關係，可確保優先獲得正在研發的新型寡核苷酸化學技術和抗體片段。

詳細介紹了一套嚴謹的調查方法框架，整合了定性訪談、定量資料檢驗和多源三角測量程序。

本分析採用多方面方法，整合了定性和定量資料。初步調查包括對高級研發主管、製程開發科學家、法規事務專家以及積極參與複雜技術開發的關鍵意見領袖（KOL）進行結構化訪談。訪談通訊協定旨在捕捉他們對技術挑戰、監管預期和策略投資重點的細緻見解。

從相關人員的觀點來看，我們對影響抗體寡核苷酸複合物前景的策略需求和未來機會得出了一致的結論。

抗體特異性和寡核苷酸多功能性的融合正在為標靶治療和精準診斷建立新的範式。偶聯化學的進步、核酸療法相關法規的明確性以及合作研究舉措的拓展，都在推動這一領域的成長。儘管地緣政治趨勢和供應鏈挑戰仍然存在，但積極的多元化發展和策略夥伴關係正在降低風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 抗體-寡核苷酸複合物市場：依寡核苷酸類型分類

  • 反義寡核苷酸
  • 適體抗體複合物
  • 胜肽核酸
  • siRNA-抗體複合物

第9章 抗體-寡核苷酸複合物市場：以結合方式分類

  • 基於親和力-生物素親和性
  • 直接化學鍵
  • 基於靜電相互作用
  • 酶促結合

第10章 抗體-寡聚體複合物市場：標靶化策略

  • 細胞表面受體
  • 細胞內標靶
  • 病原體相關標靶

第11章 抗體-寡核苷酸複合物市場：依應用分類

  • 診斷
  • 研究
  • 治療
    • 自體免疫疾病
    • 循環系統疾病
    • 感染疾病
    • 神經系統疾病
    • 腫瘤學
    • 罕見疾病

第12章 抗體寡核苷酸偶聯物市場：依最終用戶分類

  • 學術和研究機構
  • 製藥和生物技術公司

第13章 抗體-寡核苷酸複合物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗體寡聚體複合物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗體-寡聚體複合物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗體-寡核苷酸複合物市場

第17章：中國抗體-寡核苷酸複合物市場

第18章 競爭格局

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Abzena Holdings (USA) LLC
  • Agilent Technologies Inc.
  • AstraZeneca PLC
  • Avidity Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Danaher Corporation
  • Eli Lilly and Company
  • GenScript BIoTech Corporation
  • Goodwin BIoTechnology Inc.
  • Ionis Pharmaceuticals, Inc.
  • Rockland Immunochemicals, Inc
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Tallac Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd
Product Code: MRR-4F7A6D4FD72D

The Antibody-oligonucleotide Conjugates Market was valued at USD 3.15 billion in 2024 and is projected to grow to USD 3.42 billion in 2025, with a CAGR of 8.89%, reaching USD 5.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.15 billion
Estimated Year [2025] USD 3.42 billion
Forecast Year [2030] USD 5.26 billion
CAGR (%) 8.89%

Exploring the Foundations and Significance of Antibody-Oligonucleotide Conjugates in Advancing Precision Medicine and Diagnostic Innovation

Antibody-oligonucleotide conjugates represent a frontier in biotherapeutic innovation, combining the target specificity of monoclonal antibodies with the regulatory finesse of nucleic acid technologies. Emerging as a versatile class of conjugates, they enable precise delivery of genetic payloads to defined cellular populations, opening new vistas in targeted therapy and advanced diagnostics. Leveraging bespoke chemistries that tether oligonucleotides to antibody scaffolds, researchers are overcoming historical delivery challenges to achieve enhanced tissue penetration and minimized off-target effects.

This convergence of two potent modalities is driven by a clear vision: harnessing molecular specificity to address complex disease mechanisms. In recent years, breakthroughs in linker design, site-specific conjugation, and oligonucleotide stabilization have coalesced to transform theoretical constructs into tangible clinical assets. Consequently, stakeholders across pharmaceutical, academic, and biotechnology sectors are channeling resources into refining these conjugates, anticipating both therapeutic breakthroughs and next-generation diagnostic tools.

Moreover, the alignment of regulatory guidelines with innovation pipelines has accelerated timelines for investigational new drug submissions. As a result, antibody-oligonucleotide research is transitioning from bench-scale proof-of-concept studies to early-phase clinical trials, signifying a pivotal shift in the paraphernalia of precision medicine. In this report, the foundational landscape is mapped out to guide strategic decisions and illuminate the opportunities inherent in this dynamic field.

Identifying the Transformative Technological Shifts Reshaping Antibody-Oligonucleotide Conjugate Development from Bench to Bedside Integration Scenarios

Innovation in conjugation chemistry and molecular design has catalyzed transformative shifts in the field of antibody-oligonucleotide conjugates. In recent years, advancements in site-specific attachment strategies have eliminated heterogeneous populations of conjugates, leading to reproducible pharmacokinetics and predictable biodistribution. Simultaneously, novel linker constructs with tunable stability profiles have empowered researchers to fine-tune release kinetics, thereby enhancing therapeutic indices and mitigating immunogenicity.

Beyond chemistry, integration of in silico modeling and high-throughput screening has optimized oligonucleotide sequences for both affinity and specificity, reducing development timelines and resource expenditure. As a result, platform technologies are emerging that enable plug-and-play assembly of antibody and oligonucleotide modules. Moreover, the maturation of regulatory frameworks for nucleic acid therapies has provided clearer pathways for preclinical validation, driving greater alignment between discovery teams and regulatory authorities.

Furthermore, increased collaboration between academic consortia and industrial research centers has fostered knowledge transfer, enabling rapid iteration on design principles and accelerating the transition from discovery to clinical proof of concept. These transformative shifts collectively signal a maturation of the antibody-oligonucleotide conjugate ecosystem, setting the stage for the next wave of targeted therapeutics and diagnostic solutions.

Evaluating the Cumulative Consequences of Imposed United States Tariffs for 2025 on Supply Chains Research Investments and Cross-Border Collaborations

In 2025, the implementation of new United States tariffs has introduced a layer of complexity to the supply chains supporting antibody-oligonucleotide conjugate manufacturing. Increased duties on critical reagents such as modified oligonucleotides and specialized antibodies are contributing to elevated input costs. Consequently, research budgets are being reallocated to buffer these additional expenses, leading to strategic shifts in sourcing and vendor selection.

Furthermore, the tariffs have incentivized onshoring of reagent production, prompting stakeholders to evaluate domestic partnerships and localized manufacturing capabilities. In addition, cross-border collaborations are being renegotiated to account for the financial impact of tariff differentials, particularly for organizations relying on integrated supply networks in Europe and Asia-Pacific. As a direct outcome, lead times for critical components are being reassessed, and contingency planning has become a central focus of project management discussions.

Despite these headwinds, some organizations are viewing this as an opportunity to strengthen supply resilience. By diversifying procurement channels and investing in strategic inventory buffers, companies are striving to maintain research momentum while mitigating cost exposure. In this context, the cumulative impact of these tariffs extends beyond immediate financial considerations to reshape strategic planning, risk management, and long-term partnership agreements across the antibody-oligonucleotide conjugate landscape.

Unveiling Critical Segmentation Insights Across Oligonucleotide Types Conjugation Methodologies Targeting Strategies Applications and End Users

A clear understanding of how the market divides across critical parameters offers actionable intelligence. When examining the system based on oligonucleotide type, distinct trends emerge: antisense oligonucleotides continue to demonstrate robust target knockdown potential, while siRNA-antibody conjugates leverage RNA interference pathways for transient gene silencing. Aptamer-antibody conjugates stand out for their dual recognition capabilities, and peptide nucleic acids bring unparalleled stability into the therapeutic milieu.

Conjugation methodology further stratifies the landscape. Enzymatic conjugation approaches provide unparalleled site specificity, whereas direct chemical linkages deliver streamlined scalability. Electrostatic interaction-based assemblies afford reversible attachment, and affinity-driven avidin-biotin systems offer modularity, each method tailored to particular development imperatives and manufacturing constraints.

Targeting strategy sheds additional light on application opportunities. Conjugates aimed at cell surface receptors enable precise tissue-specific delivery, whereas those designed for intracellular targets require careful navigation of membrane translocation barriers. Pathogen-associated target conjugates are carving a niche in infectious disease applications, highlighting the versatility of this class.

Application-centric segmentation underscores divergent end uses. Diagnostic implementations capitalize on high-affinity binding for biomarker detection, research applications exploit modular design for mechanistic studies, and therapeutic deployments span autoimmune disorders, cardiovascular diseases, infectious diseases, neurological disorders, oncology, and rare diseases. The plurality of therapeutic areas underscores the platform's adaptability.

Finally, end-user perspectives differentiate demand dynamics. Academic and research institutions prioritize foundational understanding and experimental flexibility, while pharmaceutical and biotechnology companies emphasize scalability, regulatory alignment, and commercialization potential.

Dissecting Key Regional Dynamics Influencing Antibody-Oligonucleotide Conjugate Adoption and Growth Patterns across Americas EMEA and Asia-Pacific

Regional dynamics exert a profound influence on the development and adoption of antibody-oligonucleotide conjugates. In the Americas, established biopharmaceutical hubs and robust venture funding ecosystems continue to accelerate early-stage research and translational partnerships. This region's regulatory bodies have also demonstrated proactive alignment with novel therapy frameworks, facilitating streamlined pathways to clinical evaluation.

Across Europe, the Middle East, and Africa, the emphasis on harmonized regulatory standards is fostering collaborative clinical networks and pan-regional consortia. Investment in precision medicine infrastructure has increased, particularly in consortium-led initiatives that seek to integrate cutting-edge conjugate platforms into national healthcare strategies. Moreover, emerging centers of excellence are positioning the region as both a research incubator and a manufacturing base for conjugate components.

In the Asia-Pacific region, economic growth and government-led biotechnology initiatives are catalyzing significant expansion in local manufacturing capacity. Cost-competitive production combined with scaling of contract research networks is attracting global partnerships. Additionally, patient populations with high unmet medical needs are driving localized clinical research, and favorable intellectual property regulations in certain jurisdictions are encouraging technology transfer and joint ventures.

Highlighting Leading Corporate Strategies and Innovations Driving Competitive Edge in the Antibody-Oligonucleotide Conjugate Domain Global Players Overview

Leading organizations in the antibody-oligonucleotide conjugate arena are differentiating through proprietary platform technologies and strategic alliances. Innovative biotechnology firms are forging collaborations with academic centers to gain early access to novel linker chemistries and oligonucleotide modifications. Conversely, established pharmaceutical companies are integrating conjugate platforms into broader biologics pipelines, leveraging in-house manufacturing expertise to expedite scale-up.

Partnerships between instrument providers and therapeutic developers are also on the rise, enabling seamless end-to-end workflows from conjugate synthesis to analytical validation. Strategic alliances are extending into contract research organization networks, granting developers access to specialized capabilities in cell-based assays, pharmacokinetic analysis, and toxicology studies tailored for conjugate modalities.

In parallel, certain niche technology firms are differentiating through advanced computational tools that predict conjugate stability and optimize sequence design. Their integration into drug discovery workflows is demonstrating potential for reducing development timelines and improving lead candidate selection. Together, these corporate strategies highlight a competitive landscape driven by collaborative models, platform scalability, and the pursuit of first-mover advantage in key therapeutic segments.

Delivering Actionable Strategic Recommendations to Guide Industry Leaders through Innovation Optimization and Collaborative Partnerships in Conjugate Therapeutics

Industry leaders should prioritize the establishment of flexible manufacturing ecosystems capable of accommodating diverse conjugation methodologies. By investing in modular production lines, organizations can switch seamlessly between enzymatic, chemical, and affinity-based approaches in response to project-specific requirements. Furthermore, forging early-stage collaborations with raw material suppliers will secure preferential access to novel oligonucleotide chemistries and antibody fragments under development.

In addition, companies should cultivate cross-functional teams that integrate computational modeling, analytical chemistry, and regulatory expertise. Such multidisciplinary units can drive rapid prototyping of conjugates, ensuring that design iterations are informed by both in silico predictions and empirical validation. Equally important is engaging proactively with regulatory authorities to define clear experimental endpoints and mitigate potential approval bottlenecks.

To address geopolitical and supply chain uncertainties, it is advisable to diversify procurement across regions and explore dual sourcing for critical reagents. Establishing strategic inventory buffers will safeguard research continuity, while localized partnerships can reduce tariff exposure and lead time variability. Finally, organizations should explore co-development agreements with clinical networks to accelerate translational studies in high-priority therapeutic areas, thereby aligning organizational capabilities with market needs and patient demands.

Detailing Rigorous Research Methodology Framework Incorporating Qualitative Interviews Quantitative Data Validation and Multisource Triangulation Procedures

This analysis is grounded in a multi-pronged methodology that synthesizes qualitative and quantitative inputs. Primary research involved structured interviews with senior R&D executives, process development scientists, regulatory affairs specialists, and key opinion leaders actively engaged in conjugate technology development. Interview protocols were designed to capture nuanced perspectives on technical challenges, regulatory expectations, and strategic investment priorities.

Complementing these insights, secondary research encompassed an exhaustive review of patent filings, regulatory guidance documents, peer-reviewed literature, and white papers from leading scientific organizations. A specialized database was constructed to track novel conjugation chemistries, linker innovations, and oligonucleotide modifications, ensuring that the report reflects the latest advancements in the field.

Data triangulation was employed to validate findings across sources, enabling the reconciliation of disparate insights and the identification of consistent trends. Comparative analysis of case studies and clinical trial registries provided real-world context for development progress and translational success. Together, these methodological layers underpin the credibility and robustness of the report's conclusions and strategic recommendations.

Drawing Consistent Conclusions on the Strategic Imperatives and Future Opportunities Shaping the Antibody-Oligonucleotide Conjugate Landscape with Stakeholder Perspectives

The convergence of antibody specificity and oligonucleotide versatility is establishing a new paradigm for targeted therapeutics and precision diagnostics. Growth is being propelled by advancements in conjugation chemistries, enhanced regulatory clarity for nucleic acid therapies, and an expanding base of collaborative research initiatives. While geopolitical dynamics and supply chain considerations present challenges, proactive diversification and strategic partnerships are mitigating risk.

Segment-specific insights reveal that siRNA-based conjugates and antisense modalities are driving early translational momentum, underpinned by robust targeting strategies and modular platform designs. Regional dynamics underscore the importance of localized manufacturing and regulatory harmonization, with the Americas leading in early-stage research, EMEA fostering collaborative clinical networks, and Asia-Pacific accelerating scale-up through government-backed initiatives.

Corporate landscapes are being defined by partnerships that bridge discovery platforms with manufacturing capabilities, and by computational tools that refine sequence design. Strategic recommendations for industry leaders coalesce around flexible production ecosystems, integrated multidisciplinary teams, and proactive engagement with regulatory bodies. Ultimately, antibody-oligonucleotide conjugates stand poised to transform the therapeutic and diagnostic landscape, offering a versatile toolkit to address unmet medical needs with unprecedented precision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibody-oligonucleotide Conjugates Market, by Oligonucleotide Type

  • 8.1. Antisense Oligonucleotide
  • 8.2. Aptamer-Antibody Conjugates
  • 8.3. Peptide Nucleic Acids
  • 8.4. siRNA-Antibody Conjugates

9. Antibody-oligonucleotide Conjugates Market, by Conjugation Methodology

  • 9.1. Avidin-biotin Affinity-based
  • 9.2. Direct Chemical Linkage
  • 9.3. Electrostatic Interaction-based
  • 9.4. Enzymatic Conjugation

10. Antibody-oligonucleotide Conjugates Market, by Targeting Strategy

  • 10.1. Cell Surface Receptors
  • 10.2. Intracellular Targets
  • 10.3. Pathogen-Associated Targets

11. Antibody-oligonucleotide Conjugates Market, by Application

  • 11.1. Diagnostics
  • 11.2. Research
  • 11.3. Therapeutics
    • 11.3.1. Autoimmune Disorders
    • 11.3.2. Cardiovascular Diseases
    • 11.3.3. Infectious Diseases
    • 11.3.4. Neurological Disorders
    • 11.3.5. Oncology
    • 11.3.6. Rare Diseases

12. Antibody-oligonucleotide Conjugates Market, by End-User

  • 12.1. Academic & Research Institutions
  • 12.2. Pharmaceutical & Biotechnology Companies

13. Antibody-oligonucleotide Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antibody-oligonucleotide Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antibody-oligonucleotide Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antibody-oligonucleotide Conjugates Market

17. China Antibody-oligonucleotide Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2024
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2024
  • 18.3. Product Portfolio Analysis, 2024
  • 18.4. Benchmarking Analysis, 2024
  • 18.5. AbbVie Inc.
  • 18.6. Abzena Holdings (US) LLC
  • 18.7. Agilent Technologies Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Avidity Biosciences, Inc.
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Danaher Corporation
  • 18.12. Eli Lilly and Company
  • 18.13. GenScript Biotech Corporation
  • 18.14. Goodwin Biotechnology Inc.
  • 18.15. Ionis Pharmaceuticals, Inc.
  • 18.16. Rockland Immunochemicals, Inc
  • 18.17. Sanofi SA
  • 18.18. Sarepta Therapeutics, Inc.
  • 18.19. Tallac Therapeutics, Inc.
  • 18.20. Thermo Fisher Scientific Inc.
  • 18.21. WuXi AppTec Co., Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 13. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMER-ANTIBODY CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMER-ANTIBODY CONJUGATES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMER-ANTIBODY CONJUGATES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PEPTIDE NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PEPTIDE NUCLEIC ACIDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PEPTIDE NUCLEIC ACIDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA-ANTIBODY CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA-ANTIBODY CONJUGATES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA-ANTIBODY CONJUGATES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AVIDIN-BIOTIN AFFINITY-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AVIDIN-BIOTIN AFFINITY-BASED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AVIDIN-BIOTIN AFFINITY-BASED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT CHEMICAL LINKAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT CHEMICAL LINKAGE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT CHEMICAL LINKAGE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ELECTROSTATIC INTERACTION-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ELECTROSTATIC INTERACTION-BASED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ELECTROSTATIC INTERACTION-BASED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ENZYMATIC CONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ENZYMATIC CONJUGATION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ENZYMATIC CONJUGATION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CELL SURFACE RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CELL SURFACE RECEPTORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CELL SURFACE RECEPTORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRACELLULAR TARGETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRACELLULAR TARGETS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRACELLULAR TARGETS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PATHOGEN-ASSOCIATED TARGETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PATHOGEN-ASSOCIATED TARGETS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PATHOGEN-ASSOCIATED TARGETS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 121. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. AFRICA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 136. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. ASEAN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 140. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 143. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 145. GCC ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 157. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 159. BRICS ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 164. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. G7 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 171. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 173. NATO ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONJUGATION METHODOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY TARGETING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA ANTIBODY-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)